Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INFORM2-NivEnt
NL-OMON60435Phase 2Active, not recruiting
- Sponsor
- Heidelberg University Hospital
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab and entinostat in Refractory malignant neoplasm, cancer, central nervous system tumor and 1 more (5 arms), sponsored by Heidelberg University Hospital. Primary endpoints: Dose Limiting Toxicity and Best response. Started Sep 2019; status: active, not recruiting.
02
Drugs
nivolumabentinostat
03
Conditions
Refractory malignant neoplasmcancercentral nervous system tumorNonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON60435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60435.